Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Parkinsonism Relat Disord. 2018 Mar;48:34-39. doi: 10.1016/j.parkreldis.2017.12.007. Epub 2017 Dec 9.
Mutations in the LRRK2 and alpha-synuclein (SNCA) genes are well-established causes of autosomal dominant Parkinson's disease (PD). However, their frequency differs widely between ethnic groups. Only three studies have screened all coding regions of LRRK2 and SNCA in European samples so far. In Turkey, the role of LRRK2 in Parkinson's disease has been studied fragmentarily, and the incidence of SNCA copy number variations is unknown. The purpose of this study is to determine the frequency of LRRK2 and SNCA mutations in autosomal dominant PD in Turkey.
We performed Sanger sequencing of all coding LRRK2 and SNCA exons in a sample of 91 patients with Parkinsonism. Copy number variations in SNCA, PRKN, PINK1, DJ1 and ATP13A2 were assessed using the MLPA method. All patients had a positive family history compatible with autosomal dominant inheritance.
Known mutations in LRRK2 and SNCA were found in 3.3% of cases: one patient harbored the LRRK2 G2019S mutation, and two patients carried a SNCA gene duplication. Furthermore, we found a heterozygous deletion of PRKN exon 2 in one patient, and four rare coding variants of unknown significance (LRRK2: A211V, R1067Q, T2494I; SNCA: T72T). Genetic testing in one affected family identified the LRRK2 R1067Q variant as a possibly pathogenic substitution.
Point mutations in LRRK2 and SNCA are a rare cause of autosomal dominant PD in Turkey. However, copy number variations should be considered. The unclassified variants, especially LRRK2 R1067Q, demand further investigation.
LRRK2 和 alpha-突触核蛋白 (SNCA) 基因突变是常染色体显性帕金森病 (PD) 的明确病因。然而,它们在不同种族之间的频率差异很大。迄今为止,只有三项研究在欧洲样本中筛选了 LRRK2 和 SNCA 的所有编码区。在土耳其,LRRK2 在帕金森病中的作用仅被零星研究过,SNCA 拷贝数变异的发病率尚不清楚。本研究旨在确定 LRRK2 和 SNCA 突变在土耳其常染色体显性 PD 中的频率。
我们对 91 例帕金森病患者的所有编码 LRRK2 和 SNCA 外显子进行了 Sanger 测序。使用 MLPA 方法评估 SNCA、PRKN、PINK1、DJ1 和 ATP13A2 的拷贝数变异。所有患者均有阳性家族史,符合常染色体显性遗传。
在 3.3%的病例中发现了 LRRK2 和 SNCA 的已知突变:一名患者携带 LRRK2 G2019S 突变,两名患者携带 SNCA 基因重复。此外,我们在一名患者中发现了 PRKN 外显子 2 的杂合缺失,在四名患者中发现了四个未知意义的罕见编码变异(LRRK2:A211V、R1067Q、T2494I;SNCA:T72T)。对一个受影响家族的基因检测发现 LRRK2 R1067Q 变异可能是一种致病性替代。
LRRK2 和 SNCA 的点突变是土耳其常染色体显性 PD 的罕见病因。然而,应考虑拷贝数变异。未分类的变异,尤其是 LRRK2 R1067Q,需要进一步研究。